Technical Analysis for MRSN - Mersana Therapeutics, Inc.

Grade Last Price % Change Price Change
grade D 12.27 1.49% 0.18
MRSN closed up 1.49 percent on Thursday, September 20, 2018, on 44 percent of normal volume. The stock exhibited some range contraction during this trading session as price made an NR7 -- narrowest range of the last seven sessions.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical MRSN trend table...

Date Alert Name Type % Chg
Sep 20 Calm After Storm Range Contraction 0.00%
Sep 20 Narrow Range Bar Range Contraction 0.00%
Sep 20 NR7 Range Contraction 0.00%
Sep 19 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 1.49%
Sep 19 Calm After Storm Range Contraction 1.49%
Sep 18 MACD Bearish Centerline Cross Bearish 0.82%
Sep 18 Non-ADX 1,2,3,4 Bearish Bearish Swing Setup 0.82%
Sep 18 Inside Day Range Contraction 0.82%
Sep 18 Lower Bollinger Band Touch Weakness 0.82%
Sep 17 Fell Below 20 DMA Bearish 10.14%

Older signals for MRSN ...

Get this analysis on your stocks daily!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:

Profile
Mersana Therapeutics, Inc. is a United States-based biotechnology company focused on discovering and developing a pipeline of antibody drug conjugates (ADCs). The Company focuses on advancing a pipeline of targeted oncology therapeutics leveraging its Fleximer immunoconjugate technology. The Fleximer platform allows it to design ADCs with specific properties and manage the drug's chances of attacking cancers. Its product candidates include XMT-1522 and XMT-1536. The ADC therapies treat cancer patients by engineering a drug conjugate with various anti-cancer agents and controlling when, where and how those agents are released. Dolaflexin is its Fleximer antibody drug conjugation platform, which pairs the Fleximer polymer with its linker chemistries to create ADC therapies. XMT-1522 is based on its Dolaflexin platform and has over 15 auristatin molecules per antibody. XMT-1522 is in Phase I clinical trial for various indications of cancers. XMT-1536 is in pre-clinical development.
Is MRSN a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 3 bearish and 2 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 23.96
52 Week Low 8.76
Average Volume 206,973
200-Day Moving Average 15.8663
50-Day Moving Average 13.038
20-Day Moving Average 13.442
10-Day Moving Average 13.236
Average True Range 1.1556
ADX 23.42
+DI 11.9081
-DI 24.7854
Chandelier Exit (Long, 3 ATRs ) 12.4632
Chandelier Exit (Short, 3 ATRs ) 13.7678
Upper Bollinger Band 15.2022
Lower Bollinger Band 11.6818
Percent B (%b) 0.17
BandWidth 26.189555
MACD Line -0.245
MACD Signal Line -0.038
MACD Histogram -0.207
Fundamentals Value
Market Cap 278.69 Million
Num Shares 22.7 Million
EPS -16.23
Price-to-Earnings (P/E) Ratio -0.76
Price-to-Sales 0.00
Price-to-Book 0.00
PEG Ratio 0.00
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 13.13
Resistance 3 (R3) 13.08 12.76 12.98
Resistance 2 (R2) 12.76 12.54 12.78 12.93
Resistance 1 (R1) 12.51 12.40 12.64 12.56 12.89
Pivot Point 12.19 12.19 12.25 12.21 12.19
Support 1 (S1) 11.94 11.97 12.07 11.99 11.65
Support 2 (S2) 11.62 11.83 11.64 11.61
Support 3 (S3) 11.37 11.62 11.56
Support 4 (S4) 11.42